Conditionally Activated News Today

SOUTH SAN FRANCISCO, Calif., January 03, 2024--Switch Therapeutics today announced the appointment of Charles Allerson, Ph.D., as Chief Technology Officer (CTO).

Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing toxicities seen with other targeted modalities Review includes differentiated mechanisms of action including tumor-localized activation, avidity-driven selectivity and novel SWITCH-DARPin approach ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech com

Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing toxicities...

Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing toxicities seen with other targeted modalities

Werewolf Therapeutics, Inc. announced preliminary first-in-human clinical data from initial monotherapy dose-escalation cohorts in the Company?s lead clinical program, WTX-124x2101. This clinical...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced that Dee Data, Ph.D., Co-Founder and CEO of Switch Therapeutics, will present a...

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Sanofi announced today the completion of its acquisition of Amunix Pharmaceuticals, Inc, adding a promising pipeline of T-cell engagers and cytokine therapies. The acquisition also provides access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver next generation Conditionally Activated Biologics. The ...